Boehringer Ingelheim, Inflammasome to advance new therapies for retinal diseases
German pharma giant Boehringer Ingelheim has entered into a co-development and license agreement with US-based Inflammasome Therapeutics to develop new retinal disease therapies and reduce the patient burden for eye diseases. The company is planning to develop up to three therapies for patients with retinal diseases by integrating its retinal disease pipeline portfolio compounds with […]
The post Boehringer Ingelheim, Inflammasome to advance new therapies for retinal diseases appeared first on PharmaNewsDaily.com.